Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axcella Health Inc.AXLA · Entity 116059 | President - Research & Dev. | February 08, 2022 | February 10, 2022 |
| Cartesian Therapeutics, Inc.SELB · Entity 6015 | Chief Medical Officer | January 02, 2020 | January 06, 2020 |
| Retension Pharmaceuticals, Inc.RTSN · Entity 184313 | Chief Medical Officer | October 08, 2026 | October 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axcella Health Inc.
Report date February 08, 2022 · Filed February 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.63 · Expires 2032-02-07 | Direct | 56,000 |
Reported balance
After 2022-02-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-08 · Grant · Acquired 56,000 · Balance 56,000 F1: 25% of this option shall vest and become exercisable on February 8, 2023, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of this option shall vest and become exercisable on February 8, 2023, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Cartesian Therapeutics, Inc.
Report date January 02, 2020 · Filed January 06, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.30 · Expires 2030-01-01 | Direct | 100,000 |
Reported balance
After 2020-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-01-02 · Grant · Acquired 100,000 · Balance 100,000 F1: This option will vest as to 25% on January 2, 2021. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest as to 25% on January 2, 2021. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter.
Retension Pharmaceuticals, Inc.
Report date October 08, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.43 · Expires 2036-04-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-10-08 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Granted to the Reporting Person on May 1, 2026. The stock options vest in in 1/36 monthly increments, with the first vesting date on March 23, 2026, subject to the Reporting Person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted to the Reporting Person on May 1, 2026. The stock options vest in in 1/36 monthly increments, with the first vesting date on March 23, 2026, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2022 Filed Feb 10, 2022 18:07 UTC | Axcella Health Inc. AXLA · Entity 116059 | GrantStock Option (Right to Buy) · Derivative | 56,000 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001104659-22-019555 · tm226270-2_4seq1.xml · derivative · entry 1 Schecter Alison D. · CIK 0001782448 · President - Research & Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires 2032-02-07 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 8, 2023, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 17:21 UTC | Axcella Health Inc. AXLA · Entity 116059 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.57 | $0.00 |
DisclosureSEC source: 0001104659-21-149610 · tm2135411-1_4seq1.xml · derivative · entry 1 Schecter Alison D. · CIK 0001782448 · President - Research & Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-03-17 F1 · kind: On March 17, 2021, the Reporting Person was granted an option to purchase 75,000 shares of AXLA common stock, which vest in three equal installments subject to the satisfaction of certain performance criteria. On December 10, 2021, the Issuer's Compensation Committee confirmed that the performance criteria had been met with regards to one installment, resulting in the vesting of 25,000 shares. F1 · derivative.exercise_date: On March 17, 2021, the Reporting Person was granted an option to purchase 75,000 shares of AXLA common stock, which vest in three equal installments subject to the satisfaction of certain performance criteria. On December 10, 2021, the Issuer's Compensation Committee confirmed that the performance criteria had been met with regards to one installment, resulting in the vesting of 25,000 shares. Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 21:27 UTC | Axcella Health Inc. AXLA · Entity 116059 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $5.57 | $0.00 |
DisclosureSEC source: 0001104659-21-038587 · tm2110273-2_4seq1.xml · derivative · entry 1 Schecter Alison D. · CIK 0001782448 · President - Research & Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-03-16 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on March 15, 2022, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 20:08 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001453687-20-000014 · wf-form4_157835929977150.xml · derivative · entry 1 Schecter Alison D. · CIK 0001782448 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-01-01 F1 · derivative.exercise_date: This option will vest as to 25% on January 2, 2021. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 16:18 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock · Derivative | 350,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001453687-19-000082 · wf-form4_156339467597510.xml · derivative · entry 1 Schecter Alison D. · CIK 0001782448 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2029-07-14 F1 · derivative.exercise_date: This option vests as to 25% on July 15, 2020, and the remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.